Trinity Biotech plc — Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual Form 20-F, not a standalone Q4 filing; separate fourth-quarter financial results are not clearly provided. Financial statements are prepared under IFRS and presented in U.S. dollars.
Business context
Trinity Biotech develops, manufactures and markets diagnostic products for clinical laboratories and point-of-care testing in approximately 100 countries. Core products address infectious diseases, HIV, diabetes and hemoglobinopathies, autoimmune diseases and clinical chemistry. In January 2024, the company entered the continuous glucose monitoring and biosensor market through its acquisition of Waveform Technologies’ assets.
2023 financial performance
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Continuing-operations revenue | US$56.8 million | US$62.5 million | Down 9.1% |
| Gross profit | US$19.5 million | US$17.3 million | Up US$2.2 million |
| Gross margin | 34.2% | 27.6% | Up 6.6 percentage points |
| Operating loss | US$27.0 million | US$19.3 million | Loss increased |
| Loss from continuing operations | US$36.9 million | US$43.6 million | Loss narrowed |
| Net loss | US$24.0 million | US$41.0 million | Loss narrowed |
| Net cash used in operating activities | US$11.6 million | US$0.9 million | Cash outflow increased |
| Cash and cash equivalents at year-end | US$3.7 million | US$6.6 million | Down US$2.9 million |
Revenue by product category was US$42.3 million from clinical laboratory goods, US$5.5 million from clinical laboratory services and US$9.1 million from point-of-care products. The Americas represented US$32.3 million, Asia/Africa US$18.9 million and Europe US$5.6 million of revenue based on customer location.
Gross margin improved primarily because 2022 included US$4.7 million of excess inventory and obsolescence charges. This improvement was more than offset at the operating level by higher selling, general and administrative expenses, increased impairment charges and lower revenue.
Liquidity, debt and capital resources
- Total indebtedness had a carrying value of approximately US$68.0 million at December 31, 2023, including the Perceptive senior secured term loan, MiCo convertible note, lease liabilities, derivative liabilities and residual exchangeable notes.
- The Perceptive term loan had a nominal outstanding balance of US$41.7 million at year-end and matures in January 2026. It is secured by substantially all of the company’s assets and subsidiary equity.
- The MiCo convertible note had a US$20.0 million nominal principal amount and a US$14.5 million carrying value. It mandatorily converts into ADSs if the stated ADS price threshold is met for five consecutive trading days.
- 2023 financing cash outflows were US$16.0 million, including US$10.1 million of term-loan repayment, a US$0.9 million early-repayment penalty, US$7.6 million of interest payments and US$2.3 million of lease payments. These outflows were partly offset by a US$5.0 million term-loan drawdown.
- Investing cash inflows were US$24.8 million, primarily reflecting US$28.2 million of net proceeds from the Fitzgerald Industries divestiture.
- Management states that the company expects to continue as a going concern and believes available cash, operating cash flow and external financing support operations for at least 12 months from the report date. However, the company has a history of operating losses and negative operating cash flow and expects to require additional capital.
Material changes versus 2022
- Revenue declined US$5.7 million, primarily due to lower COVID-19 viral transport media sales, the loss of a transplant-testing contract and lower legacy hemoglobin revenue.
- Clinical laboratory services revenue fell 25.0% after a healthcare provider moved transplant testing to another service provider.
- Point-of-care revenue was broadly stable, with a slight decline of 1.3%. Trinscreen HIV screening shipments began in Kenya in December 2023 and contributed approximately US$0.4 million of revenue.
- SG&A expense increased 15.5% to US$31.2 million, driven in part by higher professional fees, foreign-exchange losses and share-based compensation.
- Impairment charges increased to US$11.1 million from US$5.8 million. The 2023 charges included approximately US$10.8 million related to Immco and US$0.3 million related to Trinity Biotech do Brasil, plus a US$1.5 million impairment of the imaware investment.
- The company completed the sale of Fitzgerald Industries in April 2023 for approximately US$30 million of cash proceeds, recognizing a US$12.7 million gain in discontinued operations.
- Leadership changed in December 2023: John Gillard became CEO and President, Aris Kekedjian resigned as CEO, Chairman and director, and Des Fitzgerald became Interim CFO.
Outlook, guidance and unusual items
- The filing does not provide formal revenue or earnings guidance. Management expects COVID-19-related products to represent a smaller percentage of revenue in 2024.
- Management expects 2024 capitalized development expenditure of approximately US$8 million to US$10 million, primarily for CGM, biosensor technology and hemoglobin products.
- The Waveform acquisition involved initial consideration of US$12.5 million in cash and 1.8 million ADSs, plus contingent consideration with a maximum of US$20 million. The acquired assets had an estimated fair value of US$23.2 million and included US$12.1 million of goodwill and US$9.4 million of other intangible assets.
- In January 2024, Perceptive provided an additional US$22 million under an amended term-loan agreement; US$12.5 million funded the Waveform acquisition and US$9.5 million was available for general corporate purposes. The company drew an additional US$6.5 million in April 2024.
- The amended loan reduced the base rate to 8.75% plus the greater of Term SOFR or 4.0%, reduced certain repayment penalties and relaxed revenue covenants. The loan remains due in January 2026.
- The term loan includes minimum unrestricted-cash and revenue covenants. A breach could accelerate repayment and permit the lender to pursue pledged assets.
- A potential warranty claim was alleged by the purchaser of Fitzgerald Industries in March 2024, but no formal claim or supporting evidence had been received as of the financial-statement approval date; no liability was recorded.
- Nasdaq compliance remains a risk. The company regained compliance with the minimum bid-price requirement after a February 2024 ADS ratio change, but it had a separate minimum market value of publicly held shares deficiency with a stated May 20, 2024 deadline to regain compliance.
Key investor risks
- Continuing losses, negative operating cash flow and limited year-end cash create dependence on financing and successful execution of operating improvements.
- High leverage, variable-rate debt, secured collateral and the January 2026 term-loan maturity create refinancing and covenant risk.
- CGM commercialization depends on further development, clinical trials, regulatory clearances, manufacturing execution, intellectual-property protection and additional spending.
- Revenue depends substantially on distributors, public-health funding, HIV testing algorithms and government procurement programs.
- Competition, pricing pressure, supply-chain disruptions, product recalls, regulatory changes and foreign-exchange movements could adversely affect results.
- Large impairment charges and significant management estimates for intangible assets, inventory provisions and cash-generating-unit valuations may cause further earnings volatility.
- MiCo and Perceptive have significant voting influence, while options, warrants, convertible securities and the Waveform consideration may dilute existing shareholders.
Facts investors should verify
- Current cash balance, operating cash burn and availability under the amended Perceptive credit agreement.
- Compliance with the term-loan cash and revenue covenants and the company’s ability to refinance or repay the January 2026 maturity.
- 2024 Trinscreen purchase orders, Kenya algorithm litigation and the sustainability of HIV point-of-care demand.
- Waveform integration progress, CGM development milestones, regulatory timelines, required capital and contingent consideration exposure.
- Status and potential financial impact of the alleged Fitzgerald Industries warranty claim.
- Current Nasdaq market-value compliance and the potential effect of the ADS ratio change, options, warrants and convertible note on dilution.
- Whether management’s going-concern assumptions are supported by actual revenue growth, positive operating cash flow and timely financing.